Patents Examined by Jessica H. Roark
-
Patent number: 11976120Abstract: Provided herein are antibodies that selectively bind to complex comprising a non-classical HLA-I (e.g. HLA-E) and a neoantigen having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) as disclosed herein, as well as methods and uses thereof.Type: GrantFiled: March 11, 2021Date of Patent: May 7, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Jon Weidanz, Katherine Upchurch-Ange
-
Patent number: 11970544Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.Type: GrantFiled: June 21, 2021Date of Patent: April 30, 2024Assignee: GENMAB A/SInventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
-
Patent number: 11963981Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.Type: GrantFiled: May 15, 2019Date of Patent: April 23, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Evangelia Kokalaki, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Biao Ma, Mathieu Ferrari
-
Patent number: 11952410Abstract: The present disclosure provides constructs that comprise (a) a TNF-related apoptosis-inducing ligand (TRAIL) trimer comprising three consecutive extracellular TRAIL domains fused together in a head-to-tail configuration; (b) an epitope binding agent, and (c) optionally one or more additional components, wherein the epitope binding agent competitively inhibits binding of P4-TR3 or HN1-TR3 to cell surface human mesothelin. Constructs of the present disclosure induce apoptosis in cells expressing human mesothelin and a death receptor (DR4 or DR5) on the cell's surface.Type: GrantFiled: May 2, 2018Date of Patent: April 9, 2024Assignee: Washington UniversityInventors: Dirk M. Spitzer, William G. Hawkins
-
Patent number: 11945851Abstract: Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.Type: GrantFiled: June 7, 2018Date of Patent: April 2, 2024Assignee: The Wistar Institute of Anatomy and BiologyInventors: David Weiner, Elizabeth Duperret
-
Patent number: 11945864Abstract: A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.Type: GrantFiled: June 28, 2019Date of Patent: April 2, 2024Assignee: Y-BIOLOGICS INC.Inventors: Sang Pil Lee, Ji-Young Shin, Sunha Yoon, Yunseon Choi, Jae Eun Park, Ji Su Lee, Youngja Song, Gisun Baek, Seok Ho Yoo, Yeung-chul Kim, Dong Jung Lee, Bum-Chan Park, Young Woo Park
-
Patent number: 11932693Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.Type: GrantFiled: May 11, 2023Date of Patent: March 19, 2024Assignees: BioNTech SE, Genmab A/SInventors: Ugur Sahin, Sina Fellermeier-Kopf, Friederike Gieseke, Karsten Beckmann, Claudia Paulmann, Alexander Muik, Ivan Kuzmanov, Esther Cornelia Wilhelmina Breij, Patricia Garrido Castro, Jordan Blum, Lars Guelen, Joost Neijssen, Bart-Jan De Kreuk, Richard Hibbert, Janine Schuurman, Aran Frank Labrijn
-
Patent number: 11919961Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.Type: GrantFiled: December 17, 2020Date of Patent: March 5, 2024Assignee: CELLECTISInventor: Roman Galetto
-
Patent number: 11919952Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.Type: GrantFiled: January 13, 2021Date of Patent: March 5, 2024Assignee: Yuhan CorporationInventor: Heyue Zhou
-
Patent number: 11912771Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.Type: GrantFiled: March 9, 2022Date of Patent: February 27, 2024Assignee: CDR-LIFE AGInventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
-
Patent number: 11897953Abstract: This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.Type: GrantFiled: June 14, 2018Date of Patent: February 13, 2024Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Aviv Regev, Ana Carrizosa Anderson, Ayshwarya Subramanian, Orit Rozenblatt-Rosen
-
Patent number: 11890300Abstract: The present invention provides an immune effector cell that comprises a chimeric antigen receptor (CAR) specific for a tag of a tagged polypeptide, wherein said polypeptide binds to an antigen of a target cell, and a chimeric costimulatory receptor (CCR) specific for a further antigen. The CCR is not able to mediate said immune response on its own but boosts the immune response of said immune effector cell triggered by the CAR.Type: GrantFiled: December 11, 2017Date of Patent: February 6, 2024Assignee: Miltenyi Biotec B.V. & Co. KGInventors: Dominik Lock, Mario Assenmacher, Andrew Kaiser
-
Patent number: 11866514Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.Type: GrantFiled: January 30, 2020Date of Patent: January 9, 2024Assignee: GENMAB A/SInventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
-
Patent number: 11834503Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.Type: GrantFiled: June 7, 2022Date of Patent: December 5, 2023Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
-
Patent number: 11827704Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.Type: GrantFiled: July 10, 2020Date of Patent: November 28, 2023Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Patent number: 11802162Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: GrantFiled: October 25, 2019Date of Patent: October 31, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
-
Patent number: 11787875Abstract: Disclosed are materials and methods for improved single chain variable fragments.Type: GrantFiled: August 14, 2020Date of Patent: October 17, 2023Assignee: Janssen Biotech, Inc.Inventors: Jinquan Luo, Lauren Boucher, Michael Feldkamp, Michael Diem, Anthony A. Armstrong, Alexey Teplyakov, Chichi Huang
-
Patent number: 11779555Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.Type: GrantFiled: November 13, 2020Date of Patent: October 10, 2023Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim
-
Patent number: 11767368Abstract: The present application relates to an antigen-binding protein and use thereof, wherein the antigen-binding protein comprises a VH and a VL, wherein the VH comprises an HCDR1, an HCDR2 and an HCDR3, wherein the HCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 10, the HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 12, the HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 14; and the VL comprises an LCDR1, an LCDR2 and an LCDR3, wherein the LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 2, the LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 4, and the LCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 6. The present application also relates to a pharmaceutical composition comprising the antigen-binding protein and use thereof for the treatment of a cancer.Type: GrantFiled: December 5, 2022Date of Patent: September 26, 2023Assignee: UTC THERAPEUTICS (SHANGHAI) CO., LTD.Inventors: Yangbing Zhao, Xiaojun Liu, Jie Wang
-
Patent number: 11746156Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: GrantFiled: January 15, 2021Date of Patent: September 5, 2023Assignee: SORRENTO THERAPEUTICS, INC.Inventors: Heyue Zhou, John Dixon Gray